SEOUL -- Samsung Biologics is once again under scrutiny over its 2016 initial public offering as prosecutors raided the office of the Korea Exchange in Seoul on Friday.
The investigation, which follows an earlier probe into Samsung BioLogic's accounting practices ahead of the listing, is a blow for the Samsung group, which has been hoping to turn biotech into a new pillar of growth.
